Drug Profile
AV 380
Alternative Names: anti-GDF15 IgG1 mAb; Anti-GDF15 mAb; AV-380Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator St Vincents Hospital, Sydney
- Developer AVEO Oncology
- Class Monoclonal antibodies
- Mechanism of Action Growth differentiation factor 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cachexia
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Cachexia in USA (IV, Infusion)
- 13 Jun 2023 AVEO Oncology initiates a phase I trial in Cachexia in USA (IV, Infusion) (NCT05865535)
- 04 Jan 2022 AVEO Oncology completes enrolment in its phase I trial in Cachexia (In volunteers) in USA (Parenteral) (NCT04815551)